Quantinno Capital Management LP Takes $315,000 Position in SELLAS Life Sciences Group, Inc. $SLS

Quantinno Capital Management LP bought a new stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 74,378 shares of the company’s stock, valued at approximately $315,000.

Several other large investors also recently bought and sold shares of SLS. Larson Financial Group LLC purchased a new stake in SELLAS Life Sciences Group during the fourth quarter valued at $26,000. BNP Paribas Financial Markets lifted its position in SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after purchasing an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in SELLAS Life Sciences Group during the fourth quarter valued at $38,000. Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth $38,000. Finally, Money Concepts Capital Corp purchased a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth $40,000. Institutional investors own 17.38% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

NASDAQ:SLS opened at $15.46 on Monday. The stock’s fifty day moving average is $11.85 and its 200 day moving average is $7.75. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $15.88. The firm has a market capitalization of $3.12 billion, a PE ratio of -73.62 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.